A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies (DLB)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03592862
Recruitment Status :
(Pending investigation of an unexpected animal toxicology finding.)
To establish the safety and efficacy of HTL0018318 compared with placebo when administered once daily for 12 weeks to patients with dementia with Lewy bodies.
Condition or disease
Dementia With Lewy Bodies
Drug: HTL0018318Drug: Placebo
To assess the safety, tolerability and efficacy of HTL0018318 at 3 dose levels (once daily) compared with placebo over a 12-week treatment period in patients with dementia with Lewy bodies (DLB). Approximately 140 DLB patients who have not received donepezil (Aricept®) and/or other acetyl cholinesterase inhibitors (AchEi) and approximately 32 DLB patients who have had prior treatment experience with donepezil but have stopped usage will be enrolled.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
50 Years to 85 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosed with probable DLB according to the fourth revision of consensus diagnostic criteria for DLB.
Clinical imaging evidence from either SPECT or MIBG cardiac scintigraphy that is consistent with a clinical diagnosis of DLB.
Partner or caregiver able to support the patient for the duration of the clinical trial.
Patients with a diagnosis of Parkinson disease at least 1 year prior to onset of dementia.
Patients with the presence of severe extrapyramidal symptoms
Patients with the presence of an illness/condition apart from DLB that could contribute to cognitive dysfunction
Patients with poorly controlled hypertension despite lifestyle modifications and/or pharmacotherapy, who are currently on more than 2 different antihypertensive treatments
Patients with prominent, recurrent episodes of syncope are related to orthostatic hypotension
Patients with pulmonary disease or evidence of clinically significant moderate or severe pulmonary symptoms
Patients who are taking a range of prohibited and restricted medication
Patients who have been prescribed individualised cognitive rehabilitation, stimulation or training that was performed under medical supervision in the 6 months prior to the screening visit
Patients who have any known condition(s) that may be contraindicated or interfere with the completion of the nuclear imaging scans.